...
首页> 外文期刊>Bulletin of the Korean Chemical Society >Putative 3D Structure of QcrB from Mycobacterium tuberculosis Cytochrome bc1 Complex, a Novel Drug-Target for New Series of Antituberculosis Agent Q203
【24h】

Putative 3D Structure of QcrB from Mycobacterium tuberculosis Cytochrome bc1 Complex, a Novel Drug-Target for New Series of Antituberculosis Agent Q203

机译:结核分枝杆菌细胞色素bc1复合物,新系列抗结核药物Q203的新型药物靶点的QcrB的推定3D结构。

获取原文
获取原文并翻译 | 示例
           

摘要

Tuberculosis caused by Mycobacterium tuberculosis is still a serious world health problem. There is an urgent need for an effective drug against rapidly arising multiple-drug resistant M. tuberculosis (MDR-TB) and extensively drug resistant M. tuberculosis (XDR-TB) strains. Q203 was recently reported as the most promising M. tuberculosis agent, which is also active against MDR-TB and XDR-TB. The cytochrome b subunit of the cytochrome bc1 complex (QcrB) was identified as a drug target in M. tuberculosis (Rv2196) for Q203. Herein, we have built the homology models of M. tuberculosisQcrB WT and T313A mutants using the X-ray structures of other species' QcrB as templates: Rhodobacter sphaeroides, Paracoccus denitrificans, yeast and bovine. The model with the best quality based on the structural validation results was selected for docking and used for analyzing Q203-binding mode. These insightful information will be beneficial to the further development of imidazo pyridine amide series as novel antituberculosis drugs.
机译:由结核分枝杆菌引起的结核病仍然是一个严重的世界卫生问题。迫切需要一种有效的药物来对抗迅速出现的多重耐药性结核分枝杆菌(MDR-TB)和广泛耐药性结核分枝杆菌(XDR-TB)菌株。 Q203最近被报道为最有前景的结核分枝杆菌药物,对MDR-TB和XDR-TB也有活性。细胞色素bc1复合体(QcrB)的细胞色素b亚基被确定为Q203的结核分枝杆菌(Rv2196)中的药物靶标。在此,我们以其他物种QcrB的X射线结构为模板:球形红球菌,反硝化副球菌,酵母和牛,建立了结核分枝杆菌QcrB WT和T313A突变体的同源性模型。根据结构验证结果选择质量最高的模型进行对接,并用于分析Q203结合模式。这些有见地的信息将有助于进一步开发作为新型抗结核药物的咪唑并吡啶酰胺系列。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号